ClinConnect ClinConnect Logo
Search / Trial NCT04822649

Exercise Capacity According to Coronary Microvascular Dysfunction and Body Composition

Launched by KOREA UNIVERSITY ANAM HOSPITAL · Mar 29, 2021

Trial Information

Current as of July 01, 2025

Recruiting

Keywords

Body Composition, Cpet, Cfr, Coronary Microvascular Dysfunction (Cmd), Frailty, H Fp Ef

ClinConnect Summary

This clinical trial is studying how the function of tiny blood vessels in the heart and body composition (like muscle and fat levels) affect exercise capacity in patients with heart failure with preserved ejection fraction (HFpEF), a condition where the heart pumps normally but still causes symptoms like shortness of breath or chest pain. The researchers want to understand how well patients can exercise and if their heart and body conditions play a role in that.

To participate in this trial, you must be between 20 and 80 years old and experience chest pain or breathlessness, but not have serious blockages in your heart arteries. You should also be able to exercise on a treadmill or stationary bike. If you have certain heart conditions, severe kidney issues, or other specific health problems, you may not be eligible. Participants will undergo tests to evaluate their heart and body functions and may learn more about how these factors influence their ability to exercise. This study is currently looking for volunteers, and it aims to help improve understanding and treatment for people living with HFpEF.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age 20 to 80
  • Typical/atypical chest pain or ischemic symptoms including dyspnea
  • No significant coronary artery stenosis (\>50% stenosis) in coronary angiography or computed tomography
  • Left ventricular ejection fraction ≥50%
  • Exclusion Criteria:
  • More than moderate valvular heart disease
  • Congenital heart disease
  • Chronic renal failure (estimated glomerular filtration rate \<30 ml/min/1.73m2) or end-stage renal failure undergoing hemodialysis or peritoneal dialysis
  • Asthma, chronic obstructive pulmonary disease and primary pulmonary hypertension
  • Receiving anticancer drugs
  • Vasculitis associated with autoimmune diseases
  • Patients with difficulty in performing exercise load evaluation (treadmill, bicycle ergometer)
  • Atrial fibrillation
  • Atrioventricular block with more than second degrees, symptomatic bradycardia, cryo-node failure syndrome, Wolff-Parkinson-White (WPW) patients

About Korea University Anam Hospital

Korea University Anam Hospital is a leading academic medical institution in South Korea renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its state-of-the-art facilities and multidisciplinary expertise to conduct rigorous studies that aim to improve patient outcomes and contribute to medical knowledge. With a strong emphasis on ethical practices and patient safety, Korea University Anam Hospital collaborates with various stakeholders to facilitate cutting-edge research across diverse therapeutic areas, fostering an environment that promotes scientific discovery and translational medicine.

Locations

Seoul, , Korea, Republic Of

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials